Technical Analysis for TYME - Tyme Technologies, Inc.
|Grade||Last Price||% Change||Price Change|
TYME closed down 0.98 percent on Friday, January 19, 2018, on 3.67 times normal volume. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation.
|See historical TYME trend table...|
|Date||Alert Name||Type||% Chg|
|Jan 19||Shooting Star Candlestick||Bearish||0.00%|
|Jan 19||1,2,3 Pullback Bullish||Bullish Swing Setup||0.00%|
|Jan 19||Non-ADX 1,2,3,4 Bullish||Bullish Swing Setup||0.00%|
|Jan 19||Volume Surge||Other||0.00%|
|Jan 19||Wide Bands||Range Expansion||0.00%|
|Jan 19||Lower Bollinger Band Touch||Weakness||0.00%|
|Jan 19||Oversold Stochastic||Weakness||0.00%|
|Jan 18||Wide Bands||Range Expansion||-0.98%|
|Jan 18||Oversold Stochastic||Weakness||-0.98%|
|Jan 17||Hammer Candlestick||Bullish||-13.00%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Tyme Technologies, Inc., formerly Global Group Enterprises Corp., conducts majority of its research and development activities and other business operations, through its subsidiary, Tyme Inc. (Tyme). Tyme is a clinical-stage biopharmaceutical company. Tyme is focused on the development and commercialization of highly targeted cancer therapeutics with a range of oncology indications. The Company's another subsidiary, Luminant Biosciences, LLC, conducts the initial research and development of the Company's therapeutic platform. The Company is formulating its regulatory and drug development program for its lead drug candidate, SM-88, and working towards the initiation of its Phase II clinical trial. The Company is also evaluating the expansion of its Phase II program to other types of cancer. The Company has not generated any revenue.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more TYME news...
|52 Week High||9.5|
|52 Week Low||3.2|
|200-Day Moving Average||0.0|
|50-Day Moving Average||4.999|
|20-Day Moving Average||6.666|
|10-Day Moving Average||6.631|
|Average True Range||0.6537|
|Chandelier Exit (Long, 3 ATRs )||6.3389|
|Chandelier Exit (Short, 3 ATRs )||5.6211|
|Upper Bollinger Band||7.2817|
|Lower Bollinger Band||6.0503|
|Percent B (%b)||0.03|
|MACD Signal Line||0.5675|
|Market Cap||543.96 Million|
|Num Shares||89.3 Million|
|Price-to-Earnings (P/E) Ratio||-43.50|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||7.67|
|Resistance 3 (R3)||7.79||7.40||7.40|
|Resistance 2 (R2)||7.40||7.00||7.33||7.31|
|Resistance 1 (R1)||6.74||6.75||6.55||6.62||7.23|
|Support 1 (S1)||5.69||5.95||5.50||5.57||4.95|
|Support 2 (S2)||5.30||5.70||5.23||4.87|
|Support 3 (S3)||4.64||5.30||4.78|
|Support 4 (S4)||4.52|